Supplementary Methods, Table 1, Figures 1-9 from Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by &lt;i&gt;NRAS&lt;/i&gt; or &lt;i&gt;MEK&lt;/i&gt; Mutations